Tesamorelin is FDA-approved, but for a condition most people searching it have never heard of. Its only approved use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Sermorelin, CJC-1295, and ipamorelin, the peptides people usually mean, are not FDA-approved at all.
Tesamorelin is FDA-approved. It was approved in 2010 and is marketed as EGRIFTA for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. That is the only approved use. It is not approved for general weight loss, anti-aging, or athletic performance, and the peptides people often group it with, sermorelin, CJC-1295, and ipamorelin, are not FDA-approved at all.
- Tesamorelin is FDA-approved, since 2010, marketed as EGRIFTA [1]
- Its only approved indication is HIV-associated lipodystrophy in adults [1]
- Everything outside that indication is off-label, including anti-aging and general fat loss
- Sermorelin's FDA approval was withdrawn in 2009 for commercial reasons, not safety [6]
- CJC-1295 and ipamorelin have never been FDA-approved and are compounded only
What Tesamorelin Is Approved For
The approval is real and narrow. Tesamorelin was approved by the FDA in 2010 for one indication: reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. The approval rested on large randomized placebo-controlled phase 3 trials, which is what separates it from the compounded peptides.
Those trials showed a 15.2% reduction in visceral adipose tissue at 26 weeks versus placebo, with IGF-1 rising 81.0% [2], and a pooled 806-patient analysis found a 15.4% treatment effect at 26 weeks [3]. That evidence base is why the FDA granted approval, and it applies to the studied population, not the general public.
What It Is Not Approved For
- General or cosmetic weight loss: not an approved use
- Anti-aging or age-related GH decline: not an approved use
- Bodybuilding or athletic performance: not an approved use and subject to anti-doping rules
- Any use in people without HIV-associated lipodystrophy: off-label by definition
Off-label does not mean illegal for a physician to prescribe, but it does mean the use falls outside what the FDA reviewed and approved. It also means tesamorelin is priced as a specialty product rather than a wellness subscription.
One more distinction matters here. The reductions tesamorelin produced were measured in people who already had HIV-associated visceral fat accumulation, and the visceral fat reaccumulated once the drug was stopped [3]. Approval for that specific setting says nothing about how it would perform, or whether the benefit-risk balance would hold, in a healthy adult using it for aging.
How This Differs from Sermorelin, CJC-1295, and Ipamorelin
This is where the confusion usually sits. The GHRH-axis peptides marketed for age-related decline are not in the same regulatory category as tesamorelin. None of them holds a current FDA approval.
| Peptide | FDA status | How it is obtained |
|---|---|---|
| Tesamorelin | Approved 2010, HIV lipodystrophy only [1] | Commercial prescription product (EGRIFTA) |
| Sermorelin | Approval withdrawn 2009, not for safety [6] | Compounded via 503A or 503B pharmacy |
| CJC-1295 | Never FDA-approved; studied in early trials [7] | Compounded or research-channel |
| Ipamorelin | Never FDA-approved | Compounded or research-channel |
Sermorelin is the instructive case. It once held FDA approval as Geref, but the manufacturer discontinued it and the FDA determined the products were not withdrawn from sale for reasons of safety or effectiveness [6]. The withdrawal was commercial. Today sermorelin exists only as a compounded GHRH(1-29) preparation [5].
CJC-1295 was studied in healthy adults, where a single dose produced dose-dependent GH increases lasting 6 days or more and IGF-1 increases lasting 9 to 11 days [7], but it never completed the path to approval. Ipamorelin, a GHRP rather than a GHRH analog, was likewise never approved. Both are dispensed through compounding.
What FDA Approval Actually Means for Access
Approval status changes how you get the drug, what it costs, and how its quality is verified. For tesamorelin, approval means a manufactured finished product with FDA-verified identity and potency, dispensed for its indication and priced accordingly. For the compounded peptides, quality depends on the pharmacy.
- Tesamorelin: FDA-verified finished drug, specialty pricing, prescribed within its approved indication [1]
- Compounded sermorelin: quality depends on whether a 503A or 503B pharmacy fills it, with 503B held to the higher manufacturing standard
- USP 797 sterility standards and a Certificate of Analysis are the questions that matter when a product is compounded
- FDA does not verify compounded drugs for identity, potency, or sterility before they reach patients
For compounded GHRH peptides, the molecule is not the main safety variable. The pharmacy is. Ask which facility fills the prescription, whether it is 503A or 503B, and whether a Certificate of Analysis is available for your lot.
Tesamorelin is approved only for HIV-associated lipodystrophy and priced as a specialty drug. For age-related GH decline, the GHRH analog telehealth dispenses is compounded sermorelin, where the pharmacy standard and a baseline IGF-1 are what matter. SystemLabs includes baseline IGF-1 testing before prescribing, so treatment starts from a measured number.
Bottom Line
Frequently Asked Questions
Is tesamorelin FDA approved?
Yes. Tesamorelin was approved by the FDA in 2010 and is marketed as EGRIFTA [1]. Its only approved indication is reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not approved for general weight loss, anti-aging, or performance use.
What is tesamorelin approved to treat?
One condition: excess abdominal fat in HIV-infected adults with lipodystrophy [1]. The approval rested on large phase 3 trials showing roughly 15% visceral fat reduction versus placebo [2][3]. Any use outside HIV-associated lipodystrophy is off-label.
Is sermorelin FDA approved?
Not currently. Sermorelin previously held FDA approval as Geref, but the manufacturer discontinued it and the approval was withdrawn effective June 2009. The FDA determined the withdrawal was not for reasons of safety or effectiveness [6]. Sermorelin today is available only as a compounded medication [5].
Are CJC-1295 and ipamorelin FDA approved?
No. Neither CJC-1295 nor ipamorelin has ever been FDA-approved. CJC-1295 was studied in early human trials, where it produced prolonged GH and IGF-1 increases [7], but it never completed the approval path. Both are dispensed through compounding or research channels rather than as approved finished drugs.
Can I get tesamorelin without HIV?
Prescribing tesamorelin outside HIV-associated lipodystrophy is off-label. A physician can legally prescribe off-label, but the use falls outside what the FDA reviewed, and tesamorelin is priced as a specialty product. Telehealth platforms addressing age-related GH decline almost always dispense compounded sermorelin instead.
Does FDA approval make tesamorelin safer than sermorelin?
Approval means the finished product is FDA-verified for identity and potency, which compounded sermorelin is not. That is a real quality difference. It does not make the tesamorelin molecule inherently safer than the sermorelin molecule. For compounded sermorelin, the meaningful safety variable is the pharmacy, specifically whether it is 503A or 503B and whether a Certificate of Analysis is available.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness Federal Register, 78 FR 14095, 2013. FR Doc. 2013-04827. https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
